glp-1 afib Impact of Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis GLP‑1 Therapy Improves Atrial Fibrillation
Description
This Comment highlights emerging evidence and advocates for clinical strategies that prioritize muscle preservation to ensure the long-term success and safety of pharmacological weight management.
B12 deficiency affects up to 15% of adults
COVID-19 infection can complicate weight management efforts, and GLP-1 therapy adds another layer to consider
The Coming Wave of GLP-1 Competition The global success of GLP-1s has reshaped the metabolic disease landscape, driving unprecedented demand across
Medicare GLP-1 coverage for obesity begins July 1, 2026
